Welcome to our dedicated page for Telomir Pharms news (Ticker: TELO), a resource for investors and traders seeking the latest updates and insights on Telomir Pharms stock.
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company whose news flow centers on Telomir-1, its lead small-molecule candidate targeting epigenetic and metabolic drivers of cancer, aging, and age-related disease. Company press releases and corresponding 8‑K filings provide detailed updates on preclinical data, regulatory progress, and corporate developments related to this program.
Investors following TELO news will find frequent reports on oncology studies, including results in triple-negative breast cancer, prostate cancer, pancreatic cancer, and leukemia models. Recent announcements describe Telomir-1’s effects on tumor growth and metastatic spread in TNBC xenografts, reductions in PSA levels and tumor volume in prostate cancer systems, and dose-dependent cytotoxicity in aggressive leukemia cells. Other updates highlight Telomir-1’s impact on DNA methylation of tumor-suppressor genes and its inhibition of iron-dependent histone demethylases.
Another key category of Telomir news involves IND-enabling and safety milestones. The company has reported completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting favorable tolerability and consistent systemic exposure after oral dosing. These items are often disclosed both via press release and in Item 8.01 sections of Form 8‑K, giving additional regulatory context.
Corporate and strategic developments also appear in TELO’s news stream. Examples include the binding Letter of Intent to acquire TELI Pharmaceuticals, Inc. to consolidate worldwide rights to Telomir-1, and Nasdaq communications regarding listing rule compliance for annual shareholder meetings. Together, these updates provide insight into Telomir’s scientific progress, regulatory planning, and corporate positioning as it advances Telomir-1 toward potential clinical evaluation.
Telomir Pharmaceuticals (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company, has been added to the Russell 3000 and Russell Microcap Indexes as of July 1, 2024.
This inclusion follows the annual Russell indexes reconstitution, which ranks the 4,000 largest US stocks by market capitalization. Membership in these indexes signifies automatic inclusion in either the Russell 1000 or Russell 2000 indexes, impacting index funds and active investment strategies.
FTSE Russell manages these indexes, which benchmark approximately $10.5 trillion in assets. Telomir's CEO, Dr. Chris Chapman, highlighted this milestone as evidence of the company's progress since its IPO in February and its commitment to advancing Telomir-1, a potential treatment for age-related conditions.
Telomir Pharmaceuticals (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company, announced the participation of its scientific advisor, Dr. Adam Kaplin, in the Drug Information Association (DIA) 2024 Global Annual Meeting on June 17, 2024. The event, being the largest global gathering for professionals in pharmaceuticals, biotechnology, and medical devices, will feature Dr. Kaplin in a panel discussion on generative AI in clinical trials. He will discuss how AI-powered data modeling can significantly reduce time and cost in therapeutic studies while maintaining high patient safety standards. This approach has the potential to expedite drug dosing, trial performance, and patient safety by up to 90%.
Telomir Pharmaceuticals (Nasdaq: TELO) announced significant milestones for its lead product candidate, Telomir-1. The Company began a pivotal study on May 28, 2024, to evaluate the safety and efficacy of Telomir-1 in geriatric laboratory Beagle dogs over 63 days. The initial dosing was well-tolerated by all animals, aiming to treat age-related conditions like gait weakness and joint damage. Additionally, Telomir is treating a 12-year-old German Shepherd named Zeus with Telomir-1, gathering real-world data for future research and regulatory efforts. These studies are key steps towards developing treatments for both veterinary and human age-related diseases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.